A citation-based method for searching scientific literature

Bridget F Collins, Ganesh Raghu. Eur Respir Rev 2019
Times Cited: 42







List of co-cited articles
185 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
404
26

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
430
26

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
23

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
23

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
21

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
21

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
19

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Toby M Maher, Tamera J Corte, Aryeh Fischer, Michael Kreuter, David J Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg,[...]. Lancet Respir Med 2020
161
19

What's in a name? That which we call IPF, by any other name would act the same.
Athol U Wells, Kevin K Brown, Kevin R Flaherty, Martin Kolb, Victor J Thannickal. Eur Respir J 2018
121
16

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
882
16

Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Jonathan Goldin, Michael D Roth, Daniel E Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster,[...]. N Engl J Med 2006
928
16

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold,[...]. J Rheumatol 2016
127
14

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja,[...]. Lancet Respir Med 2016
392
14


Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
209
11

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
11

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
598
11

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
985
11

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Athol U Wells, Kevin R Flaherty, Kevin K Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim A Wuyts, Susanne Stowasser,[...]. Lancet Respir Med 2020
107
11

Fibrosing interstitial lung diseases: knowns and unknowns.
Vincent Cottin, Lutz Wollin, Aryeh Fischer, Manuel Quaresma, Susanne Stowasser, Sergio Harari. Eur Respir Rev 2019
66
11

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
Vincent Cottin, Nikhil A Hirani, David L Hotchkin, Anoop M Nambiar, Takashi Ogura, María Otaola, Dirk Skowasch, Jong Sun Park, Hataya K Poonyagariyagorn, Wim Wuyts,[...]. Eur Respir Rev 2018
131
11

The therapy of idiopathic pulmonary fibrosis: what is next?
Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, Nicolas Kahn, Veronika Müller, Michael Kreuter. Eur Respir Rev 2019
54
9

Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Yi Li, Haitao Li, Shuai Liu, Pinhua Pan, Xiaoli Su, Hongyi Tan, Dongdong Wu, Lemeng Zhang, Chao Song, Minhui Dai,[...]. Mol Immunol 2018
58
9


MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.
Pierre-Antoine Juge, Joyce S Lee, Esther Ebstein, Hiroshi Furukawa, Evgenia Dobrinskikh, Steven Gazal, Caroline Kannengiesser, Sébastien Ottaviani, Shomi Oka, Shigeto Tohma,[...]. N Engl J Med 2018
139
9

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
David A Lynch, Nicola Sverzellati, William D Travis, Kevin K Brown, Thomas V Colby, Jeffrey R Galvin, Jonathan G Goldin, David M Hansell, Yoshikazu Inoue, Takeshi Johkoh,[...]. Lancet Respir Med 2018
383
9

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
Aryeh Fischer, Kevin K Brown, Roland M Du Bois, Stephen K Frankel, Gregory P Cosgrove, Evans R Fernandez-Perez, Tristan J Huie, Mahalakshmi Krishnamoorthy, Richard T Meehan, Amy L Olson,[...]. J Rheumatol 2013
192
9

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.
Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C Magnus Sköld, Sara Tomassetti, Philip Hormel, John L Stauffer, Indiana Strombom,[...]. ERJ Open Res 2018
43
9

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Geetabali Sircar, Rudra Prosad Goswami, Dipankar Sircar, Alakendu Ghosh, Parasar Ghosh. Rheumatology (Oxford) 2018
79
9

Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Hayley Barnes, Anne E Holland, Glen P Westall, Nicole Sl Goh, Ian N Glaspole. Cochrane Database Syst Rev 2018
43
9

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
Aryeh Fischer, Katerina M Antoniou, Kevin K Brown, Jacques Cadranel, Tamera J Corte, Roland M du Bois, Joyce S Lee, Kevin O Leslie, David A Lynch, Eric L Matteson,[...]. Eur Respir J 2015
447
9

Update of EULAR recommendations for the treatment of systemic sclerosis.
Otylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, Mike Becker, Agnieszka Kulak, Yannick Allanore, Oliver Distler, Philip Clements, Maurizio Cutolo, Laszlo Czirjak,[...]. Ann Rheum Dis 2017
375
9

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
103
9

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Alexander Holweg, Bernhard Ryffel. J Pharmacol Exp Ther 2014
308
9

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Frank Hilberg, Gerald J Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant,[...]. Cancer Res 2008
682
9

Pirfenidone in idiopathic pulmonary fibrosis.
H Taniguchi, M Ebina, Y Kondoh, T Ogura, A Azuma, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato,[...]. Eur Respir J 2010
608
7

Role and New Insights of Pirfenidone in Fibrotic Diseases.
David Alejandro Lopez-de la Mora, Cibeles Sanchez-Roque, Margarita Montoya-Buelna, Sergio Sanchez-Enriquez, Silvia Lucano-Landeros, Jose Macias-Barragan, Juan Armendariz-Borunda. Int J Med Sci 2015
57
7

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
144
7

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Peter Saunders, Vicky Tsipouri, Gregory J Keir, Deborah Ashby, Marcus D Flather, Helen Parfrey, Daphne Babalis, Elisabetta A Renzoni, Christopher P Denton, Athol U Wells,[...]. Trials 2017
66
7

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
Kazuhiro Kurasawa, Satoko Arai, Yumeko Namiki, Ayae Tanaka, Yuta Takamura, Takayoshi Owada, Masafumi Arima, Reika Maezawa. Rheumatology (Oxford) 2018
78
7

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Zhiwei Chen, Xiaodong Wang, Shuang Ye. N Engl J Med 2019
75
7

Rituximab in severe, treatment-refractory interstitial lung disease.
Gregory J Keir, Toby M Maher, Damien Ming, Reza Abdullah, Angelo de Lauretis, M Wickremasinghe, Andrew G Nicholson, David M Hansell, Athol U Wells, Elisabetta A Renzoni. Respirology 2014
141
7

Idiopathic pulmonary fibrosis: pathogenesis and management.
Giacomo Sgalla, Bruno Iovene, Mariarosaria Calvello, Margherita Ori, Francesco Varone, Luca Richeldi. Respir Res 2018
139
7

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.
Kevin R Flaherty, Kevin K Brown, Athol U Wells, Emmanuelle Clerisme-Beaty, Harold R Collard, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Florence Le Maulf, Luca Richeldi,[...]. BMJ Open Respir Res 2017
94
7

Prevalence and prognosis of unclassifiable interstitial lung disease.
Christopher J Ryerson, Thomas H Urbania, Luca Richeldi, Joshua J Mooney, Joyce S Lee, Kirk D Jones, Brett M Elicker, Laura L Koth, Talmadge E King, Paul J Wolters,[...]. Eur Respir J 2013
154
7

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.
E J Kim, B M Elicker, F Maldonado, W R Webb, J H Ryu, J H Van Uden, J S Lee, T E King, H R Collard. Eur Respir J 2010
283
7

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Dinesh Khanna, Christopher P Denton, Angelika Jahreis, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan,[...]. Lancet 2016
295
7

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Marlies Wijsenbeek, Michael Kreuter, Amy Olson, Aryeh Fischer, Elisabeth Bendstrup, Christopher D Wells, Christopher P Denton, Baher Mounir, Leila Zouad-Lejour, Manuel Quaresma,[...]. Curr Med Res Opin 2019
51
7

Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Silvia L Bosello, Giacomo De Luca, Manuela Rucco, Giorgia Berardi, Matteo Falcione, Francesco Maria Danza, Tommaso Pirronti, Gianfranco Ferraccioli. Semin Arthritis Rheum 2015
92
7

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Rachel K Hoyles, Ross W Ellis, Jessica Wellsbury, Belinda Lees, Pauline Newlands, Nicole S L Goh, Christopher Roberts, Sujal Desai, Ariane L Herrick, Neil J McHugh,[...]. Arthritis Rheum 2006
411
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.